Discriminatory variables driving the separation observed in the OPLS-DA models.
| . | High UCEIS vs low UCEIS . | Worsening UCEIS vs improving UCEIS . | High Nancy vs low Nancy . |
|---|---|---|---|
| Lipoproteins | |||
| -CH3 | ↓ [–25%] | ↑ [31%] | ↓ [–13%] |
| (-CH2-)n | ↓ [–36%] | ↑ [49%] | ↓ [–20%] |
| βCH2 | ↓ [–37%] | ↑ [57%] | ↓ [–22%] |
| Unsaturated lipid | ↓ [–26%] | ↑ [22%] | ↓ [–17%] |
| =CH-CH2-CH2- | ↓ [–15%] | – | ↓ [–9%] |
| Branched chain amino acids | |||
| Isoleucine | ↑ [18%] | – | – |
| Valine | ↑ [21%] | – | ↑ [5%] |
| Other | |||
| Glucose | ↑ [15%] | – | ↑ [9%] |
| myo-Inositol | ↑ [26%] | ↑ [25%] | ↑ [26%] |
| Other amino acids | |||
| Lysine | – | ↓ [–10%] | – |
| Histidine | – | ↓ [–24%] | – |
| Phenylalanine | – | ↓ [–17%] | – |
| Tyrosine | – | ↓ [–23%] | – |
| . | High UCEIS vs low UCEIS . | Worsening UCEIS vs improving UCEIS . | High Nancy vs low Nancy . |
|---|---|---|---|
| Lipoproteins | |||
| -CH3 | ↓ [–25%] | ↑ [31%] | ↓ [–13%] |
| (-CH2-)n | ↓ [–36%] | ↑ [49%] | ↓ [–20%] |
| βCH2 | ↓ [–37%] | ↑ [57%] | ↓ [–22%] |
| Unsaturated lipid | ↓ [–26%] | ↑ [22%] | ↓ [–17%] |
| =CH-CH2-CH2- | ↓ [–15%] | – | ↓ [–9%] |
| Branched chain amino acids | |||
| Isoleucine | ↑ [18%] | – | – |
| Valine | ↑ [21%] | – | ↑ [5%] |
| Other | |||
| Glucose | ↑ [15%] | – | ↑ [9%] |
| myo-Inositol | ↑ [26%] | ↑ [25%] | ↑ [26%] |
| Other amino acids | |||
| Lysine | – | ↓ [–10%] | – |
| Histidine | – | ↓ [–24%] | – |
| Phenylalanine | – | ↓ [–17%] | – |
| Tyrosine | – | ↓ [–23%] | – |
Increases and decreases in metabolite concentrations in the high [>3] UCEIS cohort when compared to the low [≤3] UCEIS cohort, in the worsening compared to the improving UCEIS cohorts, and the high [≥3] compared to the low [≤1] Nancy cohorts are indicated by arrows. Metabolites not selected by the OPLS-DA model are indicated by a dash.
Discriminatory variables driving the separation observed in the OPLS-DA models.
| . | High UCEIS vs low UCEIS . | Worsening UCEIS vs improving UCEIS . | High Nancy vs low Nancy . |
|---|---|---|---|
| Lipoproteins | |||
| -CH3 | ↓ [–25%] | ↑ [31%] | ↓ [–13%] |
| (-CH2-)n | ↓ [–36%] | ↑ [49%] | ↓ [–20%] |
| βCH2 | ↓ [–37%] | ↑ [57%] | ↓ [–22%] |
| Unsaturated lipid | ↓ [–26%] | ↑ [22%] | ↓ [–17%] |
| =CH-CH2-CH2- | ↓ [–15%] | – | ↓ [–9%] |
| Branched chain amino acids | |||
| Isoleucine | ↑ [18%] | – | – |
| Valine | ↑ [21%] | – | ↑ [5%] |
| Other | |||
| Glucose | ↑ [15%] | – | ↑ [9%] |
| myo-Inositol | ↑ [26%] | ↑ [25%] | ↑ [26%] |
| Other amino acids | |||
| Lysine | – | ↓ [–10%] | – |
| Histidine | – | ↓ [–24%] | – |
| Phenylalanine | – | ↓ [–17%] | – |
| Tyrosine | – | ↓ [–23%] | – |
| . | High UCEIS vs low UCEIS . | Worsening UCEIS vs improving UCEIS . | High Nancy vs low Nancy . |
|---|---|---|---|
| Lipoproteins | |||
| -CH3 | ↓ [–25%] | ↑ [31%] | ↓ [–13%] |
| (-CH2-)n | ↓ [–36%] | ↑ [49%] | ↓ [–20%] |
| βCH2 | ↓ [–37%] | ↑ [57%] | ↓ [–22%] |
| Unsaturated lipid | ↓ [–26%] | ↑ [22%] | ↓ [–17%] |
| =CH-CH2-CH2- | ↓ [–15%] | – | ↓ [–9%] |
| Branched chain amino acids | |||
| Isoleucine | ↑ [18%] | – | – |
| Valine | ↑ [21%] | – | ↑ [5%] |
| Other | |||
| Glucose | ↑ [15%] | – | ↑ [9%] |
| myo-Inositol | ↑ [26%] | ↑ [25%] | ↑ [26%] |
| Other amino acids | |||
| Lysine | – | ↓ [–10%] | – |
| Histidine | – | ↓ [–24%] | – |
| Phenylalanine | – | ↓ [–17%] | – |
| Tyrosine | – | ↓ [–23%] | – |
Increases and decreases in metabolite concentrations in the high [>3] UCEIS cohort when compared to the low [≤3] UCEIS cohort, in the worsening compared to the improving UCEIS cohorts, and the high [≥3] compared to the low [≤1] Nancy cohorts are indicated by arrows. Metabolites not selected by the OPLS-DA model are indicated by a dash.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
